Since the adaptive increase of antioxidant defences in cancers represents an important factor in inducing chemoresistance, several studies evidenced that a constitutive activation of Nrf2, due to increased expression or mutations in Nrf2 or its inhibitor KEAP1, contributes to the resistance to therapy in various types of cancers [200]. Here, KEAP1 is linked to cancer.